At a glance
- Originator Allergan
- Developer AbbVie
- Class Analgesics; Antiglaucomas; Antihypertensives
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cognition disorders; Glaucoma; Hypertension; Migraine; Pain
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 05 Oct 2001 No-Development-Reported for Cognition disorders in USA (Unknown route)
- 05 Oct 2001 No-Development-Reported for Glaucoma in USA (Unknown route)